ASCO 2017, 6 JUNE

Metastatic Breast Cancer at ASCO 2017 : what are the options ?

An increasing number of therapeutic options are available for the management of ER-positive, HER2-negative metastatic breast cancer, the most frequent breast cancer. If a recurrence occurs, the chemotherapy strategy if far less well defined.

Publié le : 13 Juin 2017
A A

Pr Marina Cazzaniga, Oncologist, Monza, Italy
Pr Xavier Pivot, Oncologist, Besançon, France

ASCO 2017, 6 JUNE

Metastatic Breast Cancer at ASCO 2017 : what are the options ?

Pour pouvoir accéder à cette page, vous devez vous connecter.